Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
January 8, 2020: Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalaonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
December 16, 2019: Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
November 7, 2019: Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team